The estimated Net Worth of James J Schutz is at least $117 Тысяча dollars as of 8 March 2018. James Schutz owns over 2,473 units of Sonoma Pharmaceuticals stock worth over $117,256 and over the last 8 years James sold SNOA stock worth over $0.
Sign up
James Schutz SNOA stock SEC Form 4 insiders trading
James has made over 7 trades of the Sonoma Pharmaceuticals stock since 2016, according to the Form 4 filled with the SEC. Most recently James bought 2,473 units of SNOA stock worth $9,867 on 8 March 2018.
The largest trade James's ever made was buying 2,473 units of Sonoma Pharmaceuticals stock on 8 March 2018 worth over $9,867. On average, James trades about 517 units every 38 days since 2016. As of 8 March 2018 James still owns at least 35,858 units of Sonoma Pharmaceuticals stock.
You can see the complete history of James Schutz stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's James Schutz's mailing address?
James's mailing address filed with the SEC is C/O SONOMA PHARMACEUTICALS, INC., 1129 N. MCDOWELL BLVD., PETALUMA, CA, 94954.
Insiders trading at Sonoma Pharmaceuticals
Over the last 8 years, insiders at Sonoma Pharmaceuticals have traded over $0 worth of Sonoma Pharmaceuticals stock and bought 25,155 units worth $125,359 . The most active insiders traders include Frederick J Sandford, Sharon Barbari и Robert E Miller. On average, Sonoma Pharmaceuticals executives and independent directors trade stock every 27 days with the average trade being worth of $4,840. The most recent stock trade was executed by Robert E Miller on 12 March 2018, trading 2,400 units of SNOA stock currently worth $9,744.
What does Sonoma Pharmaceuticals do?
sonoma pharmaceuticals, inc., develops and produces stabilized hypochlorous acid (hocl) products for various applications, including wound care, animal health care, eye care, oral care, and dermatological conditions in the united states and internationally. the company offers epicyn, an antimicrobial facial cleanser; levicyn, a hypochlorous acid (hocl) based prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses; celacyn gel, a product indicated to promote healing through the management of new and old scars resulting from surgical procedures and trauma wounds or burns; sebuderm, a product indicated to manage and relieve the burning, itching, pain, and distraction associated with seborrhea and seborrheic dermatitis; and ceramax, a lipogrid based skin barrier cream for management of dry itchy skin, minor skin irritations, rashes, and inflammation caused by various skin conditions, as well as loyon for the management of skin scal
What does Sonoma Pharmaceuticals's logo look like?
Complete history of James Schutz stock trades at Sonoma Pharmaceuticals
Sonoma Pharmaceuticals executives and stock owners
Sonoma Pharmaceuticals executives and other stock owners filed with the SEC include:
-
Bruce Thornton,
Chief Operating Officer, Secretary -
Bruce Thornton,
COO & Corp. Sec. -
Amy M. Trombly,
CEO & Pres -
Amy Trombly,
Chief Executive Officer -
Jerome Dvonch,
Chief Financial Officer -
Philippe Weigerstorfer,
Independent Director -
Jay Birnbaum,
Independent Director -
Sharon Barbari,
Independent Director -
Jerry McLaughlin,
Lead Independent Director -
Jerry Dvonch,
Chief Financial Officer -
Victoria Covel,
Assistant Controller -
Dr. Robert Northey,
Exec. VP of R&D -
Russell Joseph Harrison,
Director -
John Mclaughlin,
Director -
Marc Umscheid,
Chief Strategy/Mkt Officer -
Robert Grant Edwards,
Chief Financial Officer -
Poggetto John Dal,
Controller -
Robert Allen Northey,
Exec. VP of Res & Development -
James J Schutz,
-
Robert E Miller,
-
Frederick J Sandford,
CEO and Interim CFO -
Chad Norman White,
Chief Financial Officer -
Jerome J Dvonch,
Chief Financial Officer